Nortis

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

Lyora Therapeutics develops genetic medicines for inherited retinal diseases that currently have no treatment.

Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.

Kuehnle Agrosystems, Inc. specializes in biotech research and development of plant-based systems used for producing biologically active compounds. Originally known as Kuehnle Agrosystems Company, LLC, the company was established in 2007 and is located in Honolulu, Hawaii.

ETI have fostered a protected, novel clinical gadget that eliminates galectin-3 from human blood. The gadget eliminates both bound and free galectin-3 from the course, offering another treatment choice that is less obtrusive and has less aftereffects than different treatments. The single-use apheresis segment specifically eliminates Galectin-3 from the body. It contains an exclusive, profoundly powerful catching particle and is underlying an organization that medical clinics definitely know how to utilize.

Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.

Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.

Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.